Patents by Inventor Richard O'Hara, Jr.

Richard O'Hara, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of IL-12 and IL-12 Antagonists in the Treatment of Autoimmune Diseases
    Publication number: 20130089515
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Application
    Filed: July 31, 2012
    Publication date: April 11, 2013
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, JR.
  • Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
    Patent number: 8231874
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: July 31, 2012
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
  • USE OF IL-12 AND IL-12 ANTAGONISTS IN THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20120020916
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Application
    Filed: July 28, 2011
    Publication date: January 26, 2012
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, JR.
  • Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
    Patent number: 8012475
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: September 6, 2011
    Assignee: Genetics Institute, LLC
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
  • Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
    Publication number: 20090263351
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Application
    Filed: May 14, 2009
    Publication date: October 22, 2009
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, JR.
  • Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
    Patent number: 7534430
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: May 19, 2009
    Assignee: Genetics Institute, LLC
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
  • Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
    Patent number: 7138115
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Grant
    Filed: September 11, 2003
    Date of Patent: November 21, 2006
    Assignee: Genetics Institute, LLC
    Inventors: John P. Leonard, Samuel Goldman, Richard O'Hara, Jr.
  • Use of IL-12 antagonists in the treatment of rheumatoid arthritis
    Patent number: 6830751
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-&ggr; or TNF-&agr;. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: December 14, 2004
    Assignee: Genetics Institute, LLC
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
  • Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
    Patent number: 6706264
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-&ggr; or TNF-&agr;. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: March 16, 2004
    Assignee: Genetics Institute, LLC
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
  • Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
    Patent number: 6338848
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-&ggr; or TNF-&agr;. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: January 15, 2002
    Assignee: Genetics Institute, Inc.
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.